EBMC-710GO / Kalohexis - LARVOL DELTA

Kalohexis…announced that data supporting dual melanocortin-3 receptor/melanocortin-4 receptor (MC3R/MC4R) activation as a novel mechanism to enable meaningful weight loss with favorable weight-loss quality and limited rebound in obese nonhuman primates is being featured in a poster presentation at the International Congress on Obesity 2026 (ICO 2026)… (PRNewswire) - "The data, previously presented at ENDO 2026, highlight the potential of Kalohexis' oral dual MC3R/MC4R agonist, 710GO..."

Preclinical • Obesity

Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates (ENDO 2026) - "Building on these findings, we developed 710GO, an orally available dual MC3R/MC4R agonist that reduced caloric intake and induced significant weight loss in DIO NHPs...Given historical concerns around cardiovascular liability with melanocortin agonists, telemetry monitoring showed no changes in heart rate, blood pressure, or QTc over 24 hours at doses up to 60 mg/kg PO. Together, these data support dual MC3R/MC4R activation as a strategy to enable meaningful weight loss with favorable weight-loss quality and limited rebound in obese primates, while addressing key limitations that have historically hindered selective MC4R agonist approaches."

Cardiovascular • Genetic Disorders • Obesity • MC4R

Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates (ENDO 2026) - "Building on these findings, we developed 710GO, an orally available dual MC3R/MC4R agonist that reduced caloric intake and induced significant weight loss in DIO NHPs...Given historical concerns around cardiovascular liability with melanocortin agonists, telemetry monitoring showed no changes in heart rate, blood pressure, or QTc over 24 hours at doses up to 60 mg/kg PO. Together, these data support dual MC3R/MC4R activation as a strategy to enable meaningful weight loss with favorable weight-loss quality and limited rebound in obese primates, while addressing key limitations that have historically hindered selective MC4R agonist approaches."

Cardiovascular • Genetic Disorders • Obesity • MC4R

Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026 (PRNewswire) - "The oral presentation highlights an orally available dual MC3R/MC4R agonist that reduced caloric intake and induced significant weight loss in nonhuman primates with diet-induced obesity. Chronic oral dosing achieved 11.8% weight loss versus vehicle over 15 weeks and was followed by limited weight rebound after treatment cessation, with preferential fat mass loss and relative sparing of lean mass....710GO, Kalohexis' novel oral dual MC3R/MC4R agonist, is currently being evaluated in a Phase 1 clinical trial as a treatment for general obesity."

Preclinical • Trial status • Obesity

Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity. (PubMed, Nat Commun) - "Oral 710GO demonstrates limited weight rebound, compatibility with GLP-1-based therapies, and a favorable preclinical safety profile. These findings support combined MC3R/MC4R agonism as a promising approach for next-generation obesity therapeutics."

Journal • Genetic Disorders • Metabolic Disorders • Obesity • MC4R

Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity (PRNewswire) - "The Phase 1 randomized, double-blind, placebo-controlled, single ascending dose (SAD), 28-day multiple ascending dose (MAD), and food effect study is being conducted in Australia and is anticipated to enroll approximately 100 healthy overweight or obese volunteers. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of 710GO."

Trial status • Obesity

Melanocortin Agonism Drives Lean-Mass-Sparing Weight Loss with Increased Energy Expenditure in Obese Mice and Enhances Semaglutide-Associated Weight Loss (ENDO 2026) - "We evaluated the dual melanocortin 3/4 receptor agonist 710GO as monotherapy and in combination with semaglutide in male C57BL/6J diet-induced obese (DIO) mice...These findings support melanocortin agonism as a promising monotherapy approach for weight management and provide rationale for combination therapy with GLP-1 receptor agonists. This polytherapy strategy may enhance efficacy while potentially improving tolerability by enabling lower effective incretin doses."

Preclinical • Genetic Disorders • Obesity

Kalohexis…announced its launch and spinout from Endevica Bio, a privately-held company developing first-in-class synthetic peptidomimetics. (PRNewswire) - "Kalohexis' pipeline of assets includes 710GO, a novel, oral dual MC3R/MC4R agonist designed to activate the melanocortin system to induce higher quality, durable weight loss. Kalohexis expects to initiate a first-in-human, randomized, placebo-controlled Phase 1 clinical trial of 710GO in healthy overweight and obese volunteers in the first half of 2026....A Phase 2 trial (NCT06937177) to evaluate the safety, tolerability and efficacy of mifomelatide treating cachexia in patients with advanced colorectal cancer was initiated in Q2 2025 and is currently ongoing."

Commercial • New P1 trial • Trial status • Cachexia • Colorectal Cancer • Obesity